Edition:
United Kingdom

Bio Path Holdings Inc (BPTH.OQ)

BPTH.OQ on NASDAQ Stock Exchange Capital Market

15.00USD
17 Jul 2019
Change (% chg)

$-2.17 (-12.64%)
Prev Close
$17.17
Open
$15.63
Day's High
$16.17
Day's Low
$14.50
Volume
147,862
Avg. Vol
214,779
52-wk High
$73.52
52-wk Low
$1.63

Latest Key Developments (Source: Significant Developments)

Bio-Path Holdings Reports Full Year 2018 Financial Results
Wednesday, 20 Mar 2019 

March 20 (Reuters) - Bio Path Holdings Inc ::BIO-PATH HOLDINGS REPORTS FULL YEAR 2018 FINANCIAL RESULTS.BIO PATH HOLDINGS INC - AS OF DECEMBER 31, 2018, COMPANY HAD CASH OF $1.0 MILLION, COMPARED TO $6.0 MILLION AT DECEMBER 31, 2017.BIO PATH HOLDINGS INC - ON TRACK TO SUBMIT OUR INVESTIGATIONAL NEW DRUG APPLICATION TO BEGIN A PHASE 1 STUDY OF OUR SECOND DRUG CANDIDATE, BP1002.  Full Article

Bio-Path Announces Clinical Update To Interim Analysis Of Phase 2 Prexigebersen Trial In Acute Myeloid Leukemia
Wednesday, 6 Mar 2019 

March 6 (Reuters) - Bio Path Holdings Inc ::BIO-PATH ANNOUNCES CLINICAL UPDATE TO INTERIM ANALYSIS OF PHASE 2 PREXIGEBERSEN TRIAL IN ACUTE MYELOID LEUKEMIA.BIO PATH HOLDINGS INC - INTERIM DATA UPDATE FROM PHASE 2 STUDY DEMONSTRATES MEANINGFUL CLINICAL IMPROVEMENT WITH EXCELLENT PATIENT SAFETY PROFILE.BIO PATH HOLDINGS INC - COMPANY PROVIDES CLINICAL DEVELOPMENT PLAN WITH PATHWAYS TO REGISTRATION.BIO PATH HOLDINGS INC - PATH INTENDS TO FILE FOR REGISTRATION OF BP1002 FOR TREATMENT OF VENETOCLAX RELAPSES IN BOTH CLL PATIENTS AND AML PATIENTS.  Full Article

Bio-Path Announces Clinical Update To Interim Analysis Of Phase 2 Prexigebersen Trial In Acute Myeloid Leukemia
Wednesday, 6 Mar 2019 

March 6 (Reuters) - Bio Path Holdings Inc ::BIO-PATH ANNOUNCES CLINICAL UPDATE TO INTERIM ANALYSIS OF PHASE 2 PREXIGEBERSEN TRIAL IN ACUTE MYELOID LEUKEMIA.BIO PATH HOLDINGS INC - INTERIM DATA UPDATE FROM PHASE 2 STUDY DEMONSTRATES MEANINGFUL CLINICAL IMPROVEMENT WITH EXCELLENT PATIENT SAFETY PROFILE.BIO PATH HOLDINGS INC - COMPANY PROVIDES CLINICAL DEVELOPMENT PLAN WITH PATHWAYS TO REGISTRATION.BIO PATH-INTENDS TO FILE FOR REGISTRATION OF BP1002 FOR TREATING VENETOCLAX RELAPSES IN BOTH CLL PATIENTS & AML PATIENTS .  Full Article

Bio-Path Holdings Announces 1-For-20 Reverse Stock Split
Friday, 18 Jan 2019 

Jan 18 (Reuters) - Bio Path Holdings Inc ::BIO-PATH HOLDINGS ANNOUNCES 1-FOR-20 REVERSE STOCK SPLIT.BIO PATH- AS RESULT OF REVERSE STOCK SPLIT, EVERY 20 SHARES OF COMMON STOCK ISSUED AND OUTSTANDING WERE CONSOLIDATED INTO 1 ISSUED AND OUTSTANDING SHARE.REVERSE STOCK SPLIT REDUCED CO’S ISSUED AND OUTSTANDING SHARES OF COMMON STOCK FROM ABOUT 22.2 MILLION TO ABOUT 1.1 MILLION.  Full Article

Bio-Path Holdings Announces Pricing Of Public Offering Of Common Stock
Tuesday, 15 Jan 2019 

Jan 14 (Reuters) - Bio Path Holdings Inc ::BIO-PATH HOLDINGS, INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 8.6 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $0.13 PER SHARE.BIO-PATH EXPECTS TO RECEIVE AGGREGATE GROSS PROCEEDS OF APPROXIMATELY $1.1 MILLION FROM OFFERING.  Full Article

Bio Path Holdings Inc Says Board Approved Ratio For Reverse Stock Split Of 1-For-20
Monday, 14 Jan 2019 

Jan 14 (Reuters) - Bio Path Holdings Inc ::BIO PATH HOLDINGS INC - ON JANUARY 11, 2019, BOARD OF DIRECTORS APPROVED A RATIO FOR REVERSE STOCK SPLIT OF 1-FOR-20.  Full Article

Bio-Path Holdings Inc Announces Proposed Public Offering Of Common Stock
Monday, 14 Jan 2019 

Jan 14 (Reuters) - Bio Path Holdings Inc ::BIO-PATH HOLDINGS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.  Full Article

Bio-Path Holdings Reports Q1 Loss Per Share $0.17
Wednesday, 16 May 2018 

May 16 (Reuters) - Bio Path Holdings Inc ::BIO-PATH HOLDINGS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.17.  Full Article

Bio Path Holdings Provides Clinical Update And 2018 Business Outlook
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Bio Path Holdings Inc ::BIO-PATH HOLDINGS PROVIDES CLINICAL UPDATE AND 2018 BUSINESS OUTLOOK.BIO PATH HOLDINGS INC - ‍ANNOUNCES INITIATION OF ITS PHASE 2A CLINICAL STUDY OF PREXIGEBERSEN FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA​.BIO PATH HOLDINGS INC - INTENDS TO INITIATE A PHASE 1 CLINICAL TRIAL OF BP1002 IN 2018.  Full Article

Bio-Path Holdings Q3 loss per share $0.02
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Bio Path Holdings Inc ::Bio-Path Holdings reports third quarter 2017 financial results.Q3 loss per share $0.02.  Full Article

BUZZ-U.S. STOCKS ON THE MOVE-Eventbrite, banks, oil stocks, Big Lots, Exxon Mobil, DropCar

* Eikon search string for individual stock moves: * The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi * The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes fell on Friday, after data showed U.S. job growth almost stalled in February, adding to concerns of a slowdown in global growth sparked by weak China export data and a prolonged slowdown in the eurozone. At 11:42 ET, the Dow Jones Industrial Average was down 0.45 percent at 25,358.99